36 patents
Page 2 of 2
Utility
Combination Treatment of CD38-EXPRESSING Tumors
15 Apr 20
The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.
Jan VAN DE WINKEL, Paul PARREN, Yvo GRAUS, Judith OPRINS, Michel DE WEERS, Martine VAN VUGT, Ole BAADSGAARD, Steen LISBY
Filed: 11 Sep 19
Utility
Lyophilized anti-tissue factor antibody-drug conjugates
13 Apr 20
Disclosed herein are surfactant free lyophilized formulations of antibody-drug conjugates (ADCs), such as anti-tissue factor ADCs, and reconstituted formulations, processes and uses thereof.
Jesper Valbjørn, Xiaona Jing, Kelly Ann Roby, Timothy Warren Paul, Gregory Allan Sacha, Nathan Alan Pease, Bodil Willumsen
Filed: 20 Nov 14
Utility
Heterodimeric antibody Fc-containing proteins and methods for production thereof
23 Mar 20
Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins.
Aran Frank Labrijn, Joyce I. Meesters, Ewald T. J. Van Den Bremer, Joost J. Neijssen, Patrick Van Berkel, Bart De Goeij, Tom Vink, Jan Van De Winkel, Janine Schuurman, Paul Parren
Filed: 23 Jan 17
Utility
Inert format
16 Mar 20
Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain.
Aran Frank Labrijn, Joyce Meesters, Joost J. Neijssen, Edward Norbert Van Den Brink, Janine Schuurman, Paul Parren
Filed: 8 Jan 14
Utility
Agonistic TNF Receptor Binding Agents
11 Mar 20
The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine.
Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
Filed: 24 Sep 19
Utility
Monoclonal Antibodies Against C-met
11 Mar 20
Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed.
Joost J. NEIJSSEN, Bart DE GOEIJ, Edward Norbert VAN DEN BRINK, Aran Frank LABRIJN, Rene HOET, Janine SCHUURMAN, Paul PARREN, Jan VAN DE WINKEL
Filed: 22 Aug 19
Utility
Multispecific Antibodies Against CD40 and CD137
26 Feb 20
Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Friederike GIESEKE, Ugur SAHIN
Filed: 13 Jul 17
Utility
Production of Heterodimeric Proteins
12 Feb 20
The present invention relates to an in vitro method for production of heterodimeric proteins.
Michael GRAMER, Amitava KUNDU, Ewald T. J. VAN DEN BREMER, Muriel VAN KAMPEN, Patrick PRIEM, Aran Frank LABRIJN, Joyce I. MEESTERS, Joost J. NEIJSSEN, Janine SCHUURMAN, Paul PARREN, Patrick VAN BERKEL, Werner L. VOS, Arnout F. GERRITSEN
Filed: 29 May 19
Utility
Bispecific antibodies against CD3 and CD20
27 Jan 20
Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
Patrick Engelberts, Esther Breij, Rik Rademaker, Isil Altintas, David Satijn, Sandra Verploegen, Riemke Van Dijkhuizen Radersma, Edward Van Den Brink, Janine Schuurman, Paul Parren
Filed: 7 Jan 16
Utility
Variants of CD38 Antibody and Uses Thereof
15 Jan 20
Antibody variants comprising one or more mutations in the Fc region, particularly anti-CD38 antibodies comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index.
Bart De GOEIJ, Grietje ANDRINGA, Frank BEURSKENS, Janine SCHUURMAN, David P.E. SATIJN, Tahamtan AHMADI
Filed: 14 Jul 19
Utility
Antibodies binding AXL
23 Dec 19
The present disclosure relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
Filed: 9 Jul 15
Utility
Antibodies binding AXL
9 Dec 19
The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
Esther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
Filed: 6 Feb 19
Utility
Multispecific Antigen-binding Molecule with Improved Internalization Characteristics
20 Nov 19
The present invention relates to a multispecific antigen-binding molecule comprising a first antigen-binding domain and a second antigen-binding domain.
Bart DE GOEIJ, Joost MELIS, Tom VINK, Hendrik TEN NAPEL, Esther BREIJ, David SATIJN, Paul PARREN
Filed: 2 Feb 17
Utility
Humanized or chimeric CD3 antibodies
4 Nov 19
The present invention relates to humanized or chimeric antibodies binding CD3.
Edward Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Paul Parren
Filed: 3 Jul 14
Utility
Methods of inducing T cell activation by administering an antibody comprising CD40 and 4-1BB (CD137) binding domains
28 Oct 19
The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine.
Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
Filed: 7 Jan 16
Utility
Human Antibody Drug Conjugates Against Tissue Factor
16 Oct 19
Antibody drug conjugates against tissue factor.
David SATIJN, Sandra VERPLOEGEN, Wim BLEEKER, Steen LISBY, Jan VAN DE WINKEL, Patrick VAN BERKEL, Paul PARREN
Filed: 27 Mar 19